SIS BLU (SISBLU-30-01);SIS BLU (SISBLU-15-01)
Endoclot Plus Co., Ltd. · Decision date Sep 9, 2026
What did the FDA decide?
FDA recorded decision SESE for premarket notification K260997, dated 2026-09-09, covering the devices SIS BLU (SISBLU-30-01) and SIS BLU (SISBLU-15-01), submitted by Endoclot Plus Co., Ltd. of Suzhou, China. The record lists the medical specialty as Gastroenterology, Urology and product code PLL. In 510(k) practice, SESE denotes a substantially equivalent determination, meaning clearance to market rather than premarket approval of a new device.
The two model numbers indicate a device family submitted under one application, but the source record does not describe the device's composition, mechanism, intended use, or what distinguishes the 30-01 and 15-01 versions. No summary statement is present, and no predicate device, review timeline, or clinical evidence appears in the available data. The listed contact is Huihui Xie. Details of indications, patient selection, and use instructions would reside in the underlying FDA documents, which were not available here.
Readers should treat this as a clearance record only. The absence of a summary statement and device description limits any assessment of the technology or its regulatory basis, and no conclusion about safety or effectiveness can be drawn from the fields shown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 9, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260997
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Endoclot Plus Co., Ltd.
- Product code
- PLL
- Decision code
- SESE
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Submucosal Injection Agent.
- Applicant
- Endoclot Plus Co., Ltd.
- Product code
- PLL
- FDA device class
- 2
FDA decision timeline
K260997 received
Application receipt date recorded by FDA.
K260997 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endoclot Plus Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Suzhou
Sources and methodology
- Original FDA record: K260997
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records